CORRESP 1 filename1.htm

 

 

     

ATTORNEYS AT LAW

 

777 East Wisconsin Avenue, Suite 3800

Milwaukee, Wisconsin 53202-5306

414.271.2400 TEL

414.297.4900 FAX

www.foley.com

         
    March 14, 2019  

WRITER’S DIRECT LINE

414.297.5596

pfetzer@foley.com Email

         
       

CLIENT/MATTER NUMBER

103159-0101

 

Via EDGAR

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

 

 

Re:     Daxor Corporation - File Nos. 333-224509 and 8111-22684

 

Ladies and Gentlemen:

 

On behalf of Daxor Corporation, a New York corporation (“Daxor”), we are transmitting for filing Post-Effective Amendment No. 2 to the Registration Statement on Form N-2, File No. 333-224509 (the “Registration Statement”). Daxor, and we as their counsel, will promptly respond to any requests for additional information and will cooperate to the fullest extent with the Staff in expediting the Staff’s review of the Registration Statement.

 

This filing was made solely to update Daxor’s financial statements and make other non-material updates. Daxor has not yet sought no-action relief to allow its annual updates to go automatically effective. So, Daxor is filing its annual update on POS 8C for review.

 

In Securities Act Release No. 6510 (February 15, 1984) (the “Release”), the Division of Investment Management of the Securities and Exchange Commission (the “SEC”) announced review procedures for investment companies providing for expedited or partial review of investment company registration statements, in the discretion of the Staff, if certain conditions are met. The Release requests that information be furnished to the Staff concerning the extent to which the current filing contains disclosure information that is similar to information contained within filings that previously were reviewed by the SEC Staff.

 

The Registration Statement is substantially identical to that in Daxor’s Pre-Effective Amendment No. 5 (File Nos. 333-224509 and 8111-22684) (“Pre-Effective No. 5”), filed with the SEC on August 16, 2018, less than 7 months ago. As counsel to Daxor, we hereby request, in reliance upon the Release, that the Registration Statement receive selective review by the SEC and its Staff because of its substantial similarity to the disclosure contained in Pre-Effective No. 5.

 

Please call the undersigned at (414) 297-5596 should you have any questions regarding this filing.

 

  Very truly yours,
   
  /s/ Peter D. Fetzer
  Peter D. Fetzer

 

AUSTIN

Boston

CHICAGO

dallas

DENVER

DETROIT

houston

JACKSONVILLE

LOS ANGELES

MADISON

MEXICO CITY

MIAMI

MILWAUKEE

NEW YORK

ORLANDO

SACRAMENTO

SAN DIEGO

SAN FRANCISCO

SILICON VALLEY

TALLAHASSEE

TAMPA

WASHINGTON, D.C.

BRUSSELS

TOKYO